TAT BATTLE : NJT0401
A bifunctional fusion
protein with significant potential in immunotherapy
NJT0401 is a novel investigational fusion protein being developed to treat
Negative Breast Cancers.
The Cancer Genome Atlas (TCGA)
RNA sequencing data showed significantly greater expression of the PD-L1 gene in
Triple Negative Breast Cancer (TNBC).
As a fusion protein (made from a fusion
gene created by joining parts of two different genes with a linker), NJT0401 is
designed to block signaling pathway commonly used by cancer cells to avoid being
destroyed by the immune system, and to promote the T-cell proliferation. NJT0401
consists of a monoclonal antibody against a protein called programmed
death-ligand 1 (PD-L1) linked to the extracellular domain of the human
interleukin 2 (IL-2). Upon administration, the PD-L1 monoclonal antibody part of
NJT0401 binds PD-L1 while the IL-2 part binds to and neutralizes IL-2 receptor.
This prevents PD-L1-mediated signaling, and increases T-cell-mediated immune
response against cancer cells, ultimately inhibiting tumor cell growth.